Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

9306

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Valsartan 160 mg + nateglinide 60 mg
DRUG: Valsartan 160 mg + nateglinide placebo
DRUG: Nateglinide 60 mg + valsartan placebo
DRUG: Valsartan placebo + nateglinide placebo

Sponsor

Novartis Pharmaceuticals